Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening Products

One In Six Public Health Workers Won't Work In Emergency Flu Pandemic, According To Ben-Gurion University Of The Negev Researchers
A study conducted by researchers at Ben-Gurion University of the Negev (BGU) and John Hopkins Bloomberg School of Public Health indicates that approximately 16 percent of public health care workers will not report for work in a pandemic flu emergency, regardless of the severity.
generic viagra online
NeurogesX Provides U.S. Regulatory Update For Qutenza(TM)
NeurogesX, Inc. (Nasdaq: NGSX) announced that the U.S. Food and Drug Administration (FDA) agreed to its proposed study to evaluate Qutenza(TM) in patients with post-herpetic neuralgia (PHN) following pretreatment with an FDA-approved topical anesthetic. As part of its ongoing new drug application (NDA) review, the FDA wants to determine whether pretreatment with an FDA-approved topical anesthetic would provide similar tolerability to the topical agent used as a pretreatment in the clinical development program.
News of the day
Nationwide Telemedicine Networks Are Essential For Successful Health Care Reform
The U.S. healthcare system is in critical need of basic change to enable more equitable, effective, efficient care. Experts in various fields of medicine, public health, and industry propose that telemedicine, or information technology enhanced healthcare, must be a core component of a viable healthcare reform strategy, a view they forcefully present in a white paper published online ahead of print in Telemedicine and e-Health, a peer-reviewed journal published by Mary Ann Liebert, Inc., the official journal of the American Telemedicine Association. The white paper is available free online
Oncology

Printing New Organs: Foundation Funds Medical Technology That Replicates Human Tissue

Methuselah Foundation has identified Organovo, Inc. as a leader in the extraordinary science of bio-printing. The US Department of Health and Human Services predicts: "Within 20 years regenerative medicine will be the standard of care for replacing all tissue/organ systems in the body." Organovo, with the support of Methuselah Foundation, is applying its breakthrough organ printing technologies to make that prediction a reality. "Methuselah Foundation, through the generosity of its donors, funds multiple strategies designed to extend healthy human life," according to Dave Gobel, Founder and CEO. The MLife Sciences program of Methuselah Foundation seeks long-term strategies to combat the progressive, degenerative process of biological aging. What is accepted as "aging" is a wide range of damage that occurs at the cellular level. Our bodies show and feel the results: functionality is lost and age-related frailty, disability and disease take over. Organovo is developing a very promising solution. Their 3-dimensional bio-printer lays down bio-ink that fuses into complex tissue, creating new tissue to replace diseased tissue. Rejection of transplanted tissue is not a concern; the cells that are used can be taken from youthful progenitor cells from the patient to replace the older diseased cells. Keith Murphy, CEO of Organovo, looks ahead, "Organovo has an exciting technology platform that has attracted broad investment at a time when capital is not free flowing. The technology has immediate applications in cardiovascular therapeutics, and as the platform of choice for three dimensional tissue development. In the future Organovo hopes to provide "Tissue on Demand" for surgical applications." Organovo, Inc. is a seed-stage regenerative medicine company that applies proprietary organ printing technology to solve critical problems in transplant medicine, cardiovascular medicine, tissue repair, and medical research. Keith Murphy, CEO of Organovo, looks ahead, "Organovo has an exciting technology platform that has attracted broad investment at a time when capital is not free flowing. The technology has immediate applications in cardiovascular therapeutics, and as the platform of choice for three dimensional tissue development. In the future Organovo hopes to provide "Tissue on Demand" for surgical applications." Organovo, Inc. is a seed-stage regenerative medicine company that applies proprietary organ printing technology to solve critical problems in transplant medicine, cardiovascular medicine, tissue repair, and medical research. Methuselah Foundation is a non-profit medical charity dedicated to extending healthy human life. The Foundation supports strategies that accelerate progress toward a comprehensive cure for age-related disease, disability, and suffering. Supported by the donations of individuals and organizations, the Foundation replaces resignation with an understanding of what is possible. Methuselah Foundation"s programs include near, mid-and long-term strategies that advance the mission of ending age-related disease through awareness, education, scientific research and direct community outreach Methuselah Foundation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009